KRYS: VYJUVEK sales grew 30% as a $400M buyback accompanied delayed pipeline milestones

What happened

Krystal Biotech reported global VYJUVEK revenue growth of 30% year over year to $127.3 million, net income of $63.1 million, and more than $1.2 billion in cash and investments. Several clinical readouts shifted to 2027, guidance was lowered, and the company authorized a $400 million share buyback.

Confirmed

Global impact / market context

The sales increase and reported cash give Krystal resources, while lower guidance and delayed clinical readouts point to less favorable near-term expectations and a longer wait for pipeline results. The buyback uses company funds to repurchase shares, reducing cash available for research or other spending.

Analyst inference

For investors, the update combines stronger VYJUVEK sales with weaker guidance and later clinical milestones. Revenue growth may support the business, but delays can postpone evidence about future products; the buyback may support demand for shares while drawing on the company’s cash.

Analyst inference

What to watch

1. Watch whether VYJUVEK revenue continues growing in future updates; sustained sales would show whether the reported 30% increase is carrying forward. Analyst inference
2. Look for revised guidance details, since the article says guidance was lowered but does not give the new outlook or explain the change. Confirmed
3. Track clinical readouts shifted to 2027 and the $400 million buyback’s progress; timing and cash used could affect research funding and shares outstanding. Analyst inference

Evidence

• Original source link unavailable